ResMed announced that it has secured a victory after the United States Patent Trial and Appeals Board, or PTAB, invalidated the claims New York University, or NYU, asserted against ResMed, based on seven NYU patents. In June 2021, NYU filed a complaint for patent infringement against ResMed in the United States District Court, District of Delaware. NYU’s complaint alleged that the AutoSet and AutoRamp features of ResMed’s AirSense 10 AutoSet flow generators, infringed one or more claims of seven NYU patents. ResMed filed petitions with the PTAB asserting that all the claims asserted against ResMed were invalid. In rulings issued from December 4 to December 7, the PTAB judges, agreeing with ResMed’s arguments, found that all the challenged claims across the seven patents were invalid.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RMD:
- Study Estimates a 23% Increase in COPD by 2050, Representing 600 Million Patients Globally
- ResMed price target lowered to $160 from $180 at Mizuho
- ResMed price target lowered to $158 from $165 at Jefferies
- ResMed upgraded to Overweight at Morgan Stanley
- ResMed upgraded to Overweight from Equal Weight at Morgan Stanley